Garuda Therapeutics
Edit info- Founded: 2021
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: RD/Clin0
- Therapy area: Transfusion-dependent beta-thalassemia
- Drug types: HEM, GEN, BON
- Lead product: Undisclosed
- Funding: $62M B Feb 2023; $72M A Sep 2021
- Investors: Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, Aisling Capital, Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments
garudatx.com linkedin.com job board
Drug notes:
Undisclosed RD/Clin0 bone marrow failure
About:
Garuda Therapeutics is developing “off-the-shelf”, durable blood stem cell therapies to treat a range of diseases. Hematopoietic stem cells (HSCs) can be used to generate many different blood cell types from immune cells to red blood cells. HSCs also self renew. Currently, patients seeking a blood stem cell transplant must find a suitable donor which can place greater barriers for racial minority patients. As an alternative solution, Garuda is using their platform to generate “off-the-shelf” self-renewing HSCs to provide patients with rapid and broad access to consistent, durable and transgene-free stem cell therapies. Garuda’s blood cells have the potential to cure more than 70 diseases and eliminate the dependency on donor cells.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com